|
Steatohepatitis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The presence of steatosis was independently associated with a higher body mass index, higher levels of gamma-glutamyl transpeptidase and triglyceride, and a higher fibrosis stage.
|
19789836 |
2010 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Tissue HCV RNA levels strongly correlated with the IHC results (P<0.001, Spearman test), HCV serum load (P<0.001), aspartate aminotransferase (P=0.001), gamma-glutamyl transpeptidase (P=0.012), and aspartate aminotransferase/alanine aminotransferase ratio (P=0.029).
|
19861893 |
2009 |
|
Steatohepatitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The mean serum level of cholesterol, triglyceride, glucose, and gamma-glutamyl transpeptidase as well as the mean body mass index, viral load, stage of fibrosis and frequency of genotype 3 were significantly higher in the patients with than those without steatosis (p < 0.05).
|
18287796 |
2008 |
|
Cholestasis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Homozygous mutations in the ATP8B1 gene cause cholestasis with a normal serum gamma-glutamyl transpeptidase (gamma-GT), and have been reported in two forms of cholestasis: progressive familial intrahepatic cholestasis type 1 (PFIC1) and benign recurrent intrahepatic cholestasis (BRIC).
|
15888793 |
2005 |
|
Cholestasis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The present case, which accumulates the 3 clinical disorders assocaited with MDR3 deficiency, shows that this condition should be suspected not only in children or young people with high gamma-glutamyl transpeptidase cholestasis but also in middle-aged or older patients with chronic idiopathic cholestasis, especially when there is a previous history of cholestasis of pregnancy or juvenile cholelithiasis.
|
12671900 |
2003 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
To probe the value of gamma-glutamyl transpeptidase (GGT) messenger RNA in monitoring canceration of liver cells and for early diagnosis of hepatocellular carcinoma (HCC), by researching the types of GGT messenger RNA (GGTmRNA) in liver tissues and peripheral blood of different hepatopathy.
|
12532447 |
2003 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Five human cell lines representative of primary or metastatic tumours were investigated to study whether gamma-GT alterations could occur at the chromosomal breaks and rearrangements in ET.
|
12049636 |
2002 |
|
Cholestasis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Biochemical liver abnormalities are consistent with the presence of cholestasis and include an elevation of both serum alkaline phosphatase and gamma-glutamyl transpeptidase, with or without elevation of aminotransferase levels.
|
11918275 |
2001 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
HGV had little impact on alanine aminotransferase, aspartate aminotransferase, or gamma-glutamyl transpeptidase in donors with HGV infection alone or those coinfected with HCV.
|
10191204 |
1999 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Gamma-glutamyl transpeptidase accelerates tumor growth and increases the resistance of tumors to cisplatin in vivo.
|
10223181 |
1999 |
|
Hepatitis C
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Also, in all subjects, high gamma glutamyl transpeptidase levels (639 to 4270 IU/L), mild aspartate aminotransferase and alanine aminotransferase abnormalities, and serum HCV RNA were observed.
|
9621297 |
1998 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Since HCV viremia is often transitory and since there is no correlation between N-PCR positivity and the increase in Trans or gamma(GT) activities, HCV-RNA detection by N-PCR is probably not clinically relevant in anti-HCV+ HD patients.
|
8861802 |
1996 |
|
Hepatitis C
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In a multivariate analysis, a biochemical response (normal aminotransferase activity) at the end of treatment was significantly associated with low body weight, normal gamma-glutamyl transpeptidase activity, and a pretreatment hepatitis C virus (HCV) genotype other than 1.
|
8655978 |
1996 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In the present study, we sought to clarify the distribution of the GGTP messenger RNA (mRNA) molecular species in human liver and determine whether alterations in GGTP mRNA expression occur upon the development of HCC.
|
8621139 |
1996 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Human gamma-glutamyl transpeptidase cDNA: comparison of hepatoma and kidney mRNA in the human and rat.
|
2568315 |
1989 |
|
Fatty Liver
|
0.080 |
Biomarker
|
disease |
BEFREE |
The fatty liver index (FLI), which is calculated by the equation comprising waist circumference, body mass index (BMI), triglyceride, and gamma glutamyl transpeptidase (GGT), is frequently used for hepatic steatosis evaluation.
|
30981560 |
2020 |
|
Fibrosis, Liver
|
0.080 |
Biomarker
|
disease |
BEFREE |
The S-index calculated from γ-glutamyl transpeptidase, albumin, and platelets is reported to predict the severity of liver fibrosis.
|
30679923 |
2019 |
|
Cholestasis, progressive familial intrahepatic 1
|
0.080 |
AlteredExpression
|
disease |
BEFREE |
The severe pruritus, the early onset jaundice, poor growth and raised transaminase levels with normal gamma glutamyl transpeptidase have led to the suspicion of PFIC.
|
31630127 |
2019 |
|
Fatty Liver
|
0.080 |
Biomarker
|
disease |
BEFREE |
Univariate analysis revealed that higher age, female, lower body mass index (BMI), higher serum albumin, lower alanine aminotransferase (ALT), lower gamma-glutamyl transpeptidase, lower total bilirubin, lower α-fetoprotein, lower skeletal muscle attenuation, and liver steatosis were significantly associated with skeletal muscle volume loss.
|
29486094 |
2018 |
|
Fatty Liver
|
0.080 |
Biomarker
|
disease |
BEFREE |
High BMI (OR = 1.369, P < .001), high diastolic blood pressure (OR = 1.048, P < .001), and high gamma glutamyl transpeptidase (OR = 1.018, P = .009) were independent risk factors for liver steatosis among T2DM patients.This study suggested risk factors screening of liver fibrosis and steatosis.
|
30212992 |
2018 |
|
Fibrosis, Liver
|
0.080 |
Biomarker
|
disease |
BEFREE |
High BMI (OR = 1.369, P < .001), high diastolic blood pressure (OR = 1.048, P < .001), and high gamma glutamyl transpeptidase (OR = 1.018, P = .009) were independent risk factors for liver steatosis among T2DM patients.This study suggested risk factors screening of liver fibrosis and steatosis.
|
30212992 |
2018 |
|
Fibrosis, Liver
|
0.080 |
Biomarker
|
disease |
BEFREE |
The diagnostic performance of five common non-invasive fibrosis tests for liver fibrosis (stages S2-4), including the aspartate aminotransferase (AST)-to-platelet (PLT) ratio index (APRI), fibrosis index based on 4 factors (FIB-4), King's score, Forns index and gamma-glutamyl transpeptidase (GGT)-to-PLT ratio (GPR), were evaluated for each group.
|
30397608 |
2018 |
|
Fatty Liver
|
0.080 |
GeneticVariation
|
disease |
BEFREE |
Rs12979860 TT or rs8099917 GG genotypes as well as markers of serum and hepatocyte iron overload associated with higher activity of gamma-glutamyl transpeptidase and liver steatosis.
|
27125837 |
2017 |
|
Fatty Liver
|
0.080 |
AlteredExpression
|
disease |
BEFREE |
Ezetimibe significantly reduced serum aspartate aminotransferase, alanine aminotransferase, and γ-glutamyl transpeptidase levels, and hepatic steatosis and hepatocyte ballooning.
|
28257594 |
2017 |
|
Fibrosis, Liver
|
0.080 |
Biomarker
|
disease |
BEFREE |
The gamma-glutamyl transpeptidase to platelet ratio for non-invasive assessment of liver fibrosis in patients with chronic hepatitis B and non-alcoholic fatty liver disease.
|
28415736 |
2017 |